Market Access/ News/ News Alnylam files its third RNAi drug lumasiran in rare kidney disease Phil Taylor Alnylam, Dicerna, lumasiran, nephrology, OxThera, rare disease 0 Comment Gene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 Share X Alnylam files its third RNAi drug lumasiran in rare kidney disease https://pharmaphorum.com/news/alnylam-files-its-third-rnai-drug-lumasiran-in-rare-kidney-disease/
Alnylam, Dicerna, lumasiran, nephrology, OxThera, rare disease
0 Comment
